no delayed damage

Combining effectiveness with minimal side effects

Strong and reliable supply chain

Therapeutic isotope of the future

The FIELD-LAB team selected lead-212 as one of the key isotopes for nuclear medicine by evaluating technical achievability and the potential for medical use:

  • 1 alpha-emission in the decay chain, and 11-hour half-life 
    • long enough for targeting purposes
    • short enough and with a single alpha-emission to avoid long term off-target damage.
  • Favorable production route, strong and up scalable


Unstable isotopes that become stable through the release of alpha-radiation.

Alpha-radiation consists of highly energetic particles, that do not travel far but can create significant damage on their way

Targeted Alpha Therapy (TAT)

Effective cancer therapy by linking an alpha-emitter to a molecule that binds specifically to cancer cells. This so-called “targeting molecule” transports the alpha-emitter to the right location, preventing damage at other locations.


Karlijn van der Schilden

Karlijn van der Schilden
R&D Manager Medical Isotopes

Production of lead-212

212Pb is generated in the decay chain of 228Th.

228Th  is generated when 226Ra, a radioactive isotope that is found in nature, is exposed to neutron irradiation in a nuclear reactor.

After the 228Th is extracted from the material, it is a radioactive source which continuously generates 212Pb through radioactive decay.

212Pb can be generated by:

- Extracting it directly from the 228Th, or

- Extracting it from the intermediate decay product 224Ra, which can be extracted from the 228Th as well.

Lead 212
Lead 212

Essential nuclear facilities

Because of the significant damage alpha-emitters can cause, the materials need to be handled carefully and in a protected environment.

FIELD-LAB’s radiological laboratories allow for safe handling of alpha-emitters. Here the processes of separation and purification have been developed.

Then, these processes will be transferred to the available alpha-laboratory, where larger amounts of material can be handled and processed.

The first test batch for R&D and pre-clinical purposes will be delivered to  FIELD-LAB partners in Q4 2020.

Nuclear Infrastructure

GMP production

The last phase will be to transfer the processes to (GMP) hot cells. 212Pb, and its mother isotope 224Ra, will be produced in larger quantities and in line with the highest quality standards. This allows the material to be used for patients in a clinical research setting.

The GMP cell environment also allows manufacturing of radiopharmaceutical products, for example by linking the alpha-emitter to a cancer cell targeting molecule (labelling).

Lead 212

“Lead-212 is a very relevant medical isotope with large potential. It is however very difficult to make and have access to. FIELD-LAB allows us to proceed developing and testing the potential applications of 212Pb for effective cancer therapies.”

Experience & Partnership

With the experience collected in the FIELD-LAB partnership, and the infrastructure in Petten that was made available, we have been able to establish the production of Lead-212, a medical isotope with great perspective for cancer therapy with maximal efficiency and minimal side effects.


Directly to

drag for more
  • The world’s largest irradiator of Mo-99 targets
  • Complete supply chain in one location
  • Production process using low enriched uranium
More Information
  • Largest irradiator for lutetium-177 globally
  • Great solvability through controlled reactor circumstances
  • Predictable yield
More Information
  • Yttrium-90 in high specific and most precise activity
  • Processing and production at one hour from Amsterdam airport
  • Great solvability through controlled reactor conditions
More Information
  • Years of experience in iridium-192 production
  • Predictable, exact quality
  • Correct and safe infrastructure
More Information
  • Entire production at one single location.
  • No additional transport required from the reactor; produced in parallel with molybdenum-99
  • Low enriched uranium based (LEU)
More Information
  • Logistics department experienced in handling short lived isotopes.
  • Consulting for up-scaling of production.
  • On-site processing is possible.
More Information